Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Long-Term Capital Lease Obligation : €0.0 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi Long-Term Capital Lease Obligation?

Laboratorios Farmaceuticos Rovi's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.0 Mil.

Laboratorios Farmaceuticos Rovi's quarterly Long-Term Capital Lease Obligation increased from Sep. 2023 (€0.0 Mil) to Dec. 2023 (€13.7 Mil) but then declined from Dec. 2023 (€13.7 Mil) to Mar. 2024 (€0.0 Mil).

Laboratorios Farmaceuticos Rovi's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (€14.2 Mil) to Dec. 2022 (€13.4 Mil) but then increased from Dec. 2022 (€13.4 Mil) to Dec. 2023 (€13.7 Mil).

Laboratorios Farmaceuticos Rovi Long-Term Capital Lease Obligation Historical Data

The historical data trend for Laboratorios Farmaceuticos Rovi's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorios Farmaceuticos Rovi Long-Term Capital Lease Obligation Chart

Laboratorios Farmaceuticos Rovi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

17.41

14.48

14.22

13.40

13.67

Laboratorios Farmaceuticos Rovi Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	-	13.67	-

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Laboratorios Farmaceuticos Rovi Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ROVI:Mexico ROVIe:UK 41L:Germany

Address

Julian Camarillo, 35, Madrid, ESP, 28037

Website

https://www.rovi.es

Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.